Schering AG to Market Campath® in South East Asia
Business Review Editor
Abstract
Schering AG has acquired exclusive rights to develop, sell and distribute Ilex Oncology’s humanized monoclonal antibody Campath (alemtuzumab) in Japan, China and the Asian Pacific Basin.
Full Text: pdf
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.